Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZYMERGEN INC.

(ZY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors

11/10/2021 | 05:32pm EST

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announces that it has commenced an investigation of potential claims against the board of directors of Zymergen Inc. (“Zymergen” or the “Company”) (NASDAQ: ZY) concerning whether the board of directors breached its fiduciary duties to Zymergen shareholders.

If you still hold Zymergen shares that were purchased pursuant to or around the time of the April 2021 IPO and wish to discuss this matter with us, or have any questions concerning your rights and interests, you can submit your contact information at www.glancylaw.com/cases/zymergen-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In April 2021, Zymergen completed its IPO, selling approximately 18.5 million shares of common stock at $31 per share.

On August 3, 2021, after the market closed, Zymergen issued a business update stating that it “recently became aware of issues with its commercial product pipeline that will impact the Company’s delivery timeline and revenue projections.” Specifically, “several key target customers encountered technical issues in implementing Hyaline into their manufacturing processes,” and Zymergen also found that its total addressable market appears to be smaller than previously expected. As a result, Zymergen “no longer expects product revenue in 2021, and expects product revenue to be immaterial in 2022.” The Company also announced that its CEO was stepping down, effective immediately.

On this news, the Company’s stock price fell $26.58 per share, or 76%, to close at $8.25 per share on August 4, 2021, representing a nearly 73% decline from the IPO price.

Follow us for updates on LinkedIn, Twitter, or Facebook.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


ę Business Wire 2021
All news about ZYMERGEN INC.
01/12HSBC Upgrades Zymergen to Hold From Reduce; Lowers Price Target to $6.50 From $8
MT
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
GL
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
GL
01/10Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morg..
AQ
01/10Zymergen Launches Drug Discovery Unit
MT
01/09Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World's Large..
AQ
01/09Zymergen Announces New Drug Discovery Business Based Around Their Proprietary Synthetic..
CI
01/05Zymergen to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021ZYMERGEN ALERT : Bragar Eagel & Squire, P.C. Is Investigating Zymergen Inc. on Behalf of L..
BU
2021INSIDER BUY : Zymergen
MT
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2021 17,0 M - -
Net income 2021 -372 M - -
Net cash 2021 309 M - -
P/E ratio 2021 -1,04x
Yield 2021 -
Capitalization 488 M 488 M -
EV / Sales 2021 10,5x
EV / Sales 2022 20,0x
Nbr of Employees 758
Free-Float 90,7%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | ZY | US98985X1000 | MarketScreener
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 4,77 $
Average target price 8,80 $
Spread / Average Target 84,5%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Jed Dean Vice President-Operations & Engineering
Aaron Kimball Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.-30.49%476
BASF SE10.80%69 993
SHIN-ETSU CHEMICAL CO., LTD-11.40%63 513
DUPONT DE NEMOURS, INC.-5.31%39 630
ROYAL DSM N.V.-16.67%31 380
PIDILITE INDUSTRIES LIMITED0.45%16 625